Cowen Reiterates Hold Rating for Jounce Therapeutics (NASDAQ:JNCE)

Share on StockTwits

Jounce Therapeutics (NASDAQ:JNCE)‘s stock had its “hold” rating restated by investment analysts at Cowen in a report released on Tuesday, AnalystRatings.com reports.

Several other equities analysts have also weighed in on the stock. ValuEngine lowered shares of Jounce Therapeutics from a “sell” rating to a “strong sell” rating in a report on Tuesday, October 29th. JPMorgan Chase & Co. restated a “sell” rating on shares of Jounce Therapeutics in a report on Sunday, August 11th. Finally, Zacks Investment Research upgraded shares of Jounce Therapeutics from a “hold” rating to a “buy” rating and set a $4.50 target price on the stock in a report on Saturday. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and two have issued a buy rating to the company’s stock. Jounce Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $8.75.

Shares of JNCE traded up $0.25 during mid-day trading on Tuesday, reaching $4.95. The company had a trading volume of 46,356 shares, compared to its average volume of 114,013. The stock has a market cap of $134.91 million, a price-to-earnings ratio of -5.89 and a beta of 3.51. The firm has a fifty day simple moving average of $3.52 and a 200-day simple moving average of $4.26. Jounce Therapeutics has a fifty-two week low of $2.66 and a fifty-two week high of $7.35. The company has a current ratio of 13.60, a quick ratio of 13.60 and a debt-to-equity ratio of 0.09.

Jounce Therapeutics (NASDAQ:JNCE) last posted its earnings results on Thursday, November 7th. The company reported $2.90 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.24 by $0.66. The business had revenue of $119.45 million for the quarter, compared to analyst estimates of $99.97 million. Jounce Therapeutics had a net margin of 46.11% and a return on equity of 64.54%. As a group, equities analysts predict that Jounce Therapeutics will post 1.72 EPS for the current fiscal year.

Several large investors have recently bought and sold shares of JNCE. Meeder Asset Management Inc. lifted its holdings in shares of Jounce Therapeutics by 249.6% during the 2nd quarter. Meeder Asset Management Inc. now owns 5,034 shares of the company’s stock valued at $25,000 after acquiring an additional 3,594 shares in the last quarter. Tower Research Capital LLC TRC lifted its holdings in shares of Jounce Therapeutics by 595.8% during the 3rd quarter. Tower Research Capital LLC TRC now owns 16,073 shares of the company’s stock valued at $54,000 after acquiring an additional 13,763 shares in the last quarter. A.R.T. Advisors LLC acquired a new position in shares of Jounce Therapeutics during the 2nd quarter valued at $59,000. Bailard Inc. lifted its holdings in shares of Jounce Therapeutics by 54.1% during the 2nd quarter. Bailard Inc. now owns 22,800 shares of the company’s stock valued at $113,000 after acquiring an additional 8,000 shares in the last quarter. Finally, Russell Investments Group Ltd. acquired a new position in shares of Jounce Therapeutics during the 3rd quarter valued at $113,000. Institutional investors and hedge funds own 72.55% of the company’s stock.

About Jounce Therapeutics

Jounce Therapeutics, Inc, a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company offers vopratelimab, a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors, which is in Phase I/II clinical trial for the treatment of head and neck squamous cell cancer, non-small cell lung cancer, triple negative breast cancer, gastric cancer, and other tumor types identified through its translational science platform.

Read More: What are catch-up contributions?

Receive News & Ratings for Jounce Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Amgen, Inc.  Plans Dividend Increase – $1.60 Per Share
Amgen, Inc. Plans Dividend Increase – $1.60 Per Share
Centuria Industrial Reit Declares Interim Dividend of $0.05
Centuria Industrial Reit Declares Interim Dividend of $0.05
Stock Traders Purchase High Volume of Ciena Call Options
Stock Traders Purchase High Volume of Ciena Call Options
TokenPay  Price Down 6% Over Last Week
TokenPay Price Down 6% Over Last Week
Contents Protocol  Reaches 24-Hour Trading Volume of $79,737.00
Contents Protocol Reaches 24-Hour Trading Volume of $79,737.00
0xcert 24 Hour Trading Volume Hits $52,569.00
0xcert 24 Hour Trading Volume Hits $52,569.00


© 2006-2019 Ticker Report